D. Matthew Walentiny

Author

Also Known As

D M Walentiny, D. Matthew Walentiny, D. M. Walentiny, D. Matthew Walentiny, D. Matthew Walentiny, PhD, D.M. Walentiny, David M. Walentiny, David Matthew Walentiny, David Walentiny, Walentiny, D.

Publications

958

Citations

H-Index

Concepts

All Affiliations

Virginia Commonwealth University RTI International United States Department of Justice Scripps Research Institute Drug Enforcement Administration

About

D. Matthew Walentiny is an author at Virginia Commonwealth University specializing in medicine, pharmacology, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	15	719
2	Social Sciences	7	7	530
3	Health Sciences	3	3	100
4	Anesthesia	2	2	56
5	Behavioral Sciences	1	1	22

D. Matthew Walentiny

Publications

910

Citations

H-Index

Page 1

	Year	Citations
Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo Jonathan Z. Long, Daniel K. Nomura, Robert E. Vann, Proceedings of the National Academy of Sciences PsychopharmacologyEndocannabinoid CrosstalkPharmacotherapyDrug Discrimination BehaviorSocial Sciences	2009	385
<i>In vivo</i> characterization of the highly selective monoacylglycerol lipase inhibitor <scp>KML</scp>29: antinociceptive activity without cannabimimetic side effects Bogna M. Ignatowska‐Jankowska, Sudeshna Ghosh, Molly S. Crowe, British Journal of Pharmacology	2013	125
Opioid-like antinociceptive and locomotor effects of emerging fentanyl-related substances Neil B. Varshneya, D. Matthew Walentiny, L Moisă, Neuropharmacology Fentanyl-related SubstancesHealth SciencesFentanylPain MedicineMedicine	2019	53
Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents D. Matthew Walentiny, Robert E. Vann, Jonathan A. Warner, Psychopharmacology Cannabis UsePsychoactive DrugAddictionCannabinoid EffectsMedicine	2010	49
Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB1 receptor antagonist Jenny L. Wiley, C. S. Breivogel, Anu Mahadevan, European Journal of Pharmacology Cannabis UseMolecular PharmacologyPsychoactive DrugBiochemistryFunctional Selectivity	2010	32
Fentanyl-related substances elicit antinociception and hyperlocomotion in mice via opioid receptors Neil B. Varshneya, D. Matthew Walentiny, L Moisă, Pharmacology Biochemistry and Behavior Fentanyl-related SubstancesHealth SciencesFentanylOpioid ReceptorsPain Medicine	2021	32
Endocannabinoid contribution to Δ9-tetrahydrocannabinol discrimination in rodents Jenny L. Wiley, D. Matthew Walentiny, M. Jerry Wright, European Journal of Pharmacology Endocannabinoid ContributionCannabis UseMolecular NeuroscienceBehavioral NeuroscienceAddiction	2014	28
Effects of Acute and Repeated Administration of Oxycodone and Naloxone-Precipitated Withdrawal on Intracranial Self-Stimulation in Rats Jason M. Wiebelhaus, D. Matthew Walentiny, Patrick M. Beardsley Journal of Pharmacology and Experimental Therapeutics	2015	28
Amphetamines modulate fentanyl-depressed respiration in a bidirectional manner Harrison Elder, Neil B. Varshneya, D. Matthew Walentiny, Drug and Alcohol Dependence Molecular PharmacologyFentanyl-depressed RespirationPsychoactive DrugNeurophysiologyMedicine	2022	24
Dissimilar cannabinoid substitution patterns in mice trained to discriminate Δ9-tetrahydrocannabinol or methanandamide from vehicle Jenny L. Wiley, D. Matthew Walentiny, Robert E. Vann, Behavioural Pharmacology	2011	23

Page 1